東陽光藥(01558.HK):阿立哌唑片及利伐沙班片中標第五批全國藥品集採
格隆匯6月24日丨東陽光藥(01558.HK)發佈公吿,2021年6月23日,公司參加了國家組織藥品集中採購和使用聯合採購辦公室組織的第五批國家組織藥品集中採購的投標。公司從廣東東陽光藥業有限公司收購的阿立哌唑片及利伐沙班片中標本次集中採購。
公吿表示,上述兩種藥品的適應症所對應的市場空間廣大,隨着上述兩種藥品價格下降,其在患者中的滲透率將提高,藥品銷售量有望大幅上升,市場潛力巨大。集團後續簽訂採購合同並實施後,將迅速提高集團在兩個品種市場中的佔有率,擴大相關產品的銷售,促進公司國內市場的開拓,提升集團的品牌影響力,集團的收入結構也能得到改善,對集團的未來經營業績產生積極的影響。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.